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S U MM A R Y
S E T T I NG : The ability to rapidly distinguish between
Mycobacterium tuberculosis complex (MTC) and non-
tuberculous mycobacteria (NTM) is critical in clinical
practice.
OB J E C T I V E : To evaluate the usefulness of an immuno-
chromatographic (IC) assay to distinguish between
MTC and NTM.
DE S I GN : We analysed a panel of 145 cultures from 128
patients. The routine molecular identification approach-
es, such as the AccuProbeTM Mycobacterium tuberculo-
sis complex culture identification test and GenoTypew
Mycobacterium assays, were used as reference methods.
R E S U LT S : Of the 101 positive cultures, 98 were
correctly identified using the CapiliaTM TB-Neo Assay.
Of the three discordant isolates, one was identified as M.
bovis bacille Calmette-Gue´rin (BCG) and two as M.
tuberculosis. Although we have not performed the
sequencing of these strains, some false-negative results
have been described due to mutations in the mpb64 gene
or with some M. bovis BCG strains. We did not observe
false-positive results or any cross-reaction with 22 NTM
strains, 12 non-mycobacterial micro-organisms and 10
negative cultures.
CONC LU S I ON : We report good overall performance
(sensitivity 97%, specificity 100%, positive predictive
value 100% and negative predictive value 96%) of this
rapid assay that is easy to perform and interpret and does
not require sample preparation, trained technicians or
expensive equipment.
K E Y WORD S : mycobacteriology; tuberculosis; immu-
nochromatographic assay; diagnosis
DESPITE PROGRESS in antimicrobial chemother-
apy over the last 50 years, tuberculosis (TB) remains
one of the leading causes of death due to infection
worldwide. In 2013, 9 million persons developed TB
and 1.5 million died of the disease.1 According to the
World Health Organization’s (WHO’s) 2013 esti-
mates, TB incidence in Portugal was 26 per 100 000
population.1 Improving laboratory diagnostic ca-
pacity is a crucial component of TB control.
Moreover, there is both an increasing number of
clinical isolates of non-tuberculous mycobacteria
(NTM) in many countries and growing awareness of
their ability to cause disease.2 NTM are capable of
causing a wide range of infections in humans, with
pulmonary NTM disease being the most common,
especially in patients with pre-existing pulmonary
disease.2 NTM are mainly opportunistic pathogens
that can occasionally cause severe disseminated
disease, especially in patients with systemic impair-
ment of immunity.
The differentiation between Mycobacterium tuber-
culosis complex (MTC) and NTM is critical for TB
control as well as for clinical practice, as the
management and treatment of patients with TB
differs from that of patients infected with other
mycobacteria. Rapid confirmatory molecular tests
are available for the identification of MTC from
culture. However, these methods are comparatively
expensive and generally require technical expertise
and sophisticated equipment.
A number of immunochromatographic (IC) assays,
such as the CapiliaTM TB-Neo assay (TAUNS Labo-
ratories, Numazu, Japan), based on the detection of
the MPB64 antigen, have been developed. MPB64
has been found in unheated culture media of M.
tuberculosis, M. bovis and some, but not all,
substrains of M. bovis bacille Calmette-Gue´rin
(BCG). MPB64 is a protein that is highly specific to
the MTC. NTM do not produce MPB64.3–5 Other
tests, such as the BD MGITTM TBc Identification Test
(BD, Franklin Lakes, NJ, USA), have been developed
based on MPB64. Tests based on the MPT64 antigen,
such as the SD TB Ag MPT 64 Rapid (Standard
Diagnostics, Seoul, South Korea) have also been
developed. The Capilia TB-Neo assay is an improved
version of Capilia TB and, although this second
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generation Capilia test has been validated in some
laboratories, as with the first generation test, false-
negative results due to mutations in the mpb64 gene
have been reported.6–9
In the present study, we evaluated the performance
of the Capilia TB-Neo assay at the Clinical Pathology
Department of the S~ao Jo~ao Hospital Centre, Porto,
Portugal, in identifying MTC by comparing it with
our routine molecular identification methods.
STUDY POPULATION AND METHODS
Study population and samples
The study was conducted at the Microbiology
Laboratory of the Clinical Pathology Department of
S~ao Jo~ao Hospital Centre, the largest hospital in the
northern region of Portugal. The laboratory receives
specimens from an academic hospital and various
district hospitals. Clinical performance was deter-
mined using 145 samples from 128 patients: 101
MTC-positive cultures, 22 NTM-positive cultures,
12 other non-mycobacterial micro-organism isolates
and 10 negative cultures (growth units: 0 in BAC-
TECTM MGITTM 960 [BD] after 42 days of incuba-
tion). Clinical samples were mostly pulmonary
specimens (70 sputum, 23 bronchial lavage, 7 gastric
lavage, 5 pleural fluid, 5 bronchoalveolar lavage, 2
pleural biopsy and 1 bronchial brush), but also
included extra-pulmonary specimens (12 urine, 3
stool, 3 pericardial fluid, 1 peritoneal ganglion, 1 pus
from breast abscess, 1 pus from sternum abscess, 1
pus from bone abscess and 2 blood samples). Eight
specimens of unknown identification were also
included.
The institutional review board of S~ao Jo~ao
Hospital Centre, Porto, Portugal, approved the study.
As this was a retrospective study, the need for
informed consent was waived.
Mycobacterial culture
The samples were decontaminated using the N-
acetyl-L-cysteine-sodium hydroxide routine meth-
od.10 The digested, decontaminated and concentrated
samples were inoculated into BACTECTM MGITTM
960 medium (BD), supplemented with BBLTM MGIT
oleic albumin dextrose catalase (BD) enrichment and
BBL MGIT PANTATM antibiotic mixture (BD) or in
modified Middlebrook 7H9 broth with carbon
dioxide (CO2) BACTEC MYCO/F-Sputa (BD) and
incubated for 42 days at 378C. The MGIT 960
medium and BACTEC MYCO/F-Sputa tubes were
incubated in the BACTEC MGIT 960 and BACTEC
9000 MB (BD) systems, respectively. Four samples
were also inoculated in Lo¨wenstein-Jensen medium
(Bio-Rad Laboratories, Hercules, CA, USA) and
incubated for 60 days at 378C.
Mycobacterial molecular identification
Cultures that were positive on BACTEC MGIT 960
(manufacturer-set threshold: 75 growth units) were
examined using smear microscopy by Kinyoun’s
staining to examine acid-fast bacilli (AFB). To
determine the species of the isolates, one or two of
the following routine molecular approaches were
used as a reference identification method: the
AccuProbeTM M. tuberculosis complex culture identi-
fication test (Hologicw Inc, San Diego, CA, USA),
which relies on isothermal amplification of nucleic
acids and on oligonucleotide probes complementary
to 16S rRNA, and the GenoTypew Mycobacterium
CM and AS kits (Hain Lifescience, Nehren, Ger-
many), based on polymerase chain reaction (PCR)
and the DNA-STRIP technology.
The two molecular methods are based on the
ability of complementary nucleic acid strands to
associate to form stable double-stranded molecules.
In the first method, a single-stranded DNA probe
with a chemiluminescent label complementary to the
rRNA of the target micro-organism is used. After
RNA extraction and amplification, the selection
reagent allows discrimination of non-hybridised
probe and DNA:RNA hybrids. The hybrids are
measured in a GenProbe luminometer. In the second
method, a multiplex PCR with biotinylated primers is
performed, followed by reverse hybridisation and
addition of a streptavidin/alkaline phosphatase con-
jugate. The staining reaction is mediated by an
alkaline phosphatase. Three controls (conjugate,
universal, and genus) are included in each strip.
Capilia TB-Neo assay
The Capilia TB-Neo assay was performed according
to the manufacturer’s instructions. This IC assay uses
a nitrocellulose membrane with specific anti-MPB64
mouse monoclonal antibody immobilised on it.
Briefly, 100 ll of the positive broth culture was
applied directly into the Capilia well without any
manipulation. In positive cultures in solid media, a
few colonies from the medium were scraped using a
loop (1 ll) and suspended in 0.2 ml of extraction
buffer (TAUNS). The suspension was vortexed and
approximately 100 ll of this suspension was added to
the sample well. The results are available 15 min after
inoculation of the test cartridge. Results were read as
positive for MTC by observing the presence of
purple-red lines on the MTC area as well as on the
test area of the internal quality control.
Assessment of discordant results
Discordant results were assessed as follows: isolates
that were positive for MTC on Accuprobe or
GenoType CM but negative on Capilia TB-Neo were
tested using the GenoType MTBC assay (Hain
Lifescience), based on PCR and the DNA-STRIP
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technology according to the manufacturer’s instruc-
tions. The protocol for the GenoTypeMycobacterium
CM and AS kits is the same as described above.
Statistical analysis
The sensitivity, specificity and positive (PPV) and
negative predictive values (NPV) of the Capilia TB-
Neo assay were determined using the routine
molecular identification approaches as reference
method.
RESULTS
Of the 101 positive cultures (97 broth and 4 solid
cultures) withMTCmolecular identification, 98 were
correctly identified using the Capilia TB-Neo assay.
The test failed to detect three cultures (Tables 1 and
2). The discordant results were assessed using the
GenoType MTBC test. Of the three discordant
isolates, one was identified as M. bovis BCG and
two, isolated from the same patient in different
samples, were identified as M. tuberculosis. We did
not observe any cross-reaction with any of the 22
NTM and 12 other micro-organisms, such as
Nocardia spp., Klebsiella pneumoniae, Pseudomonas
aeruginosa, Escherichia coli, Staphylococcus aureus,
Candida albicans and Proteus mirabilis. No colour
reaction was observed in the MTC reading area in the
10 negative cultures also tested (MGIT broth cultures
that were negative on MGIT 960 after 42 days of
incubation). These results indicate a sensitivity of
97%, a specificity of 100%, a PPV of 100% and an
NPV of 96% of the Capilia TB-Neo assay for the
identification of MTC.
DISCUSSION
In this study, we evaluated the performance of an IC
assay for the identification of MTC and its differen-
tiation from NTM. We found the assay useful, with a
performance similar to that of molecular methods. In
our hospital, 19 629 samples from 10 595 patients
were analysed for mycobacteria between January
2010 and September 2014. Of the 19 629 samples, a
positive result was found in 1421 (7.2%), corre-
sponding to 650 (6.1%) patients, of whom 455
(70%) were males and 195 (30%) females, with an
average age of respectively 53 and 55 years. An NTM
strain was isolated in 253 (38.9%) of the positive
patients (153 males, 100 females). In hospitals with
high NTM prevalence, it is especially important to
rapidly differentiate between these two groups of
mycobacteria.
Molecular assays such as the AccuProbe MTC
culture identification test and GenoType Mycobacte-
rium kits are available for the identification of MTC
and NTM from cultures. However, these methods are
laborious and expensive. Various IC assays have been
developed based on the MPB64 antigen detection.
The MPB64 protein is highly specific to MTC,
including M. tuberculosis, M. africanum, M. bovis,
M. microti, M. pinnipedii, and some, although not
all, substrains of M. bovis BCG.3–5
Consistent with previous reports, the Capilia TB-
Neo assay demonstrated a specificity of 100%.7,11
We observed a sensitivity of 97%, higher than
reported by Gomanthi et al. but similar to that
reported by Muyoyeta et al. and lower than those
reported by Pokam et al. and Chikamatsu et
al.6,7,11,12 Reactivity with NTM such as M. avium,
M. kansasii, M. fortuitum, M. gordonae, M. chelo-
nae,M. peregrinum and other micro-organisms, such
as Nocardia spp., K. pneumoniae, P. aeruginosa, E.
coli, S. aureus, C. albicans and P. mirabilis, was
checked and a cross-reaction was confirmed as absent
for all of these as well as for the negative cultures
tested. Although we detected no false-positive results,
we did detect three false-negative results. The
existence of false-negative results on Capilia TB-
Neo was not further evaluated, but it may have been
due to one of the following reasons: either thempb64
gene was deleted, as previously reported for some
Table 1 Performance of the Capilia TB-Neo assay
Strain
Total
(cultures)
Positive
Capilia
assay
Negative
Capilia
assay
MTC* 101 98 3
NTM* 22 0 22
Mycobacterium
spp (n ¼ 2)
M. intracelullare (n ¼ 4)
M. avium (n ¼ 1)
M. kansasii (n ¼ 2)
M. fortuitum (n ¼ 5)
M. gordonae (n ¼ 3)
M. chelonae (n ¼ 3)
M. peregrinum (n ¼ 1)
Other micro-organisms 12 0 12
Nocardia spp. (n ¼ 3)
Klebsiella pneumoniae (n ¼ 1)
Pseudomonas aeruginosa (n ¼ 3)
Escherichia coli (n ¼ 1)
Staphylococcus aureus (n ¼ 1)
Candida albicans (n ¼ 2)
Proteus mirabilis (n ¼ 1)
Negative cultures† 10 0 10
*Routine molecular identification methods were used as reference method.
†MGIT broth cultures that were negative in BACTEC MGIT 960 system after
42 days of incubation.
MTC¼M. tuberculosis complex; NTM¼non-tuberculous mycobacteria; MGIT
¼Mycobacteria Growth Indicator Tube.
Table 2 Evaluation of the Capilia TB-Neo assay
Sensitivity
%
Specificity
%
Positive
predictive
value
%
Negative
predictive
value
%
Capilia TB-Neo 97 100 100 96
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BCG strains, such as substrains of the Pauster and
Glaxo strains,7,13 or the mpb64 gene was mutated,
leading to the production of an incomplete protein.6,7
Despite the false-negative results, we found the
sensitivity of the Capilia TB-Neo to be similar to that
observed for AccuProbe (96.8%).14 Unlike the
molecular method, the IC test is a rapid one-step test
(15 min after positivity of cultures), that is less
expensive and does not require sample preparation,
trained technicians or sophisticated equipment. These
features can simplify the identification procedure and
reduce the turnaround time for MTC identification.
CONCLUSIONS
Capilia TB-Neo is a good screening method for
rapidly identifying MTC and distinguishing between
MTC and NTM in AFB-positive cultures. As a
reduction in the laboratory turnaround time could
reduce transmission, a rapid IC confirmation test may
have important implications in TB control.
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R E S U M E
CONT EX T E : La capacite´ de distinguer rapidement le
complexe de Mycobacterium tuberculosis (MTC) et les
mycobacte´ries non-tuberculeuses (NTM) est cruciale en
termes de pratique clinique.
O B J E C T I F : E´valuer l’utilite´ d’un test
immunochromatographique afin de distinguer les
MTC des NTM.
S CH E´MA : Nous avons analyse´ un panel de 145 cultures
provenant de 128 patients. Les approches
d’identification mole´culaire de routine, comme
l’AccuProbeTM, le test d’identification par culture du
MTC et le test GenoTypew Mycobacterium, ont e´te´
utilise´es comme me´thode de re´fe´rence.
R E´ S U LTAT S : Sur 101 cultures positives, 98 ont e´te´
correctement identifie´es par le test CapiliaTM TB-Neo.
Parmi les trois isolats discordants, l’un a e´te´ identifie´
comme M. bovis du bacille Calmette-Gue´rin (BCG) et
deux autres comme M. tuberculosis. Bien que nous
n’ayons pas re´alise´ le se´quenc¸age de ces souches,
quelques re´sultats faux ne´gatifs ont e´te´ de´crits a` cause
de mutations du ge`ne mpb64 ou avec quelques souches
de M. bovis du BCG. De plus, nous n’avons pas observe´
de faux positifs ni de re´action croise´e avec les 22 NTM,
les 12 bacte´ries non-mycobacte´riennes et les 10 cultures
ne´gatives.
C O N C L U S I O N : Nous faisons e´tat d’une bonne
performance d’ensemble (sensibilite´ 97%, spe´cificite´
100%, valeur pre´dictive positive 100% et valeur
pre´dictive ne´gative 96%) de ce test rapide, facile a`
re´aliser et a` interpre´ter, qui ne demande pas de
pre´paration des e´chantillons, de techniciens forme´s ou
d’e´quipement couˆteux.
R E S UM E N
MARCO DE R E F E R ENC I A: La capacidad de diferenciar
el complejo Mycobacterium tuberculosis (MTC) y las
micobacterias no tuberculosas (NTM) es primordial en
la pra´ctica clı´nica.
O B J E T I V O: Evaluar la utilidad de una prueba
inmunocromatogra´fica en la diferenciacio´n del MTC y
las NTM.
M E´ TODO: Se analizo´ un conjunto de 145 cultivos
provenientes de 128 pacientes. Se utilizaron como
me´todos de referencia pruebas corrientes de
identificacio´n molecular como la prueba AccuProbeTM
de identificacio´n del cultivo del MTC y la prueba
GenoTypew Mycobacterium.
R E SU LTADOS: En los 101 cultivos positivos, la prueba
CapiliaTM TB-Neo detecto´ correctamente 98 muestras.
De los tres aislados discordantes, uno se identifico´ como
M. bovis bacille Calmette-Gue´rin (BCG) y dos como M.
tuberculosis. No se practico´ la secuenciacio´n de estas
cepas, pero se han descrito algunos casos de resultados
negativos falsos debido a mutaciones en el gen mpb64 o
con algunas cepas de M. bovis BCG. Adema´s, no se
observaron resultados positivos falsos ni reacciones
cruzadas con las 22 cepas de NTM ni con las otras 12
bacterias diferentes ni hubo reaccio´n en los 10 cultivos
negativos.
CON C L U S I O´ N: Los resultados del presente estudio
ponen de manifiesto un buen rendimiento diagno´stico
global (sensibilidad 97%, especificidad 100%, valor
diagno´stico de un resultado positivo 100% y valor
diagno´stico de un resultado negativo 96%) de esta
prueba ra´pida, de realizacio´n e interpretacio´n sencillas,
que no exige preparacio´n de la muestra, personal te´cnico
capacitado ni equipos costosos.
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